
TY  - JOUR
TI  - ePresentation Sessions
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 25
IS  - S2
SN  - 1351-5101
UR  - https://doi.org/10.1111/ene.13700
DO  - doi:10.1111/ene.13700
SP  - 277
EP  - 573
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts Twenty-Fourth Annual Meeting American College of Clinical Pharmacology
JO  - The Journal of Clinical Pharmacology
VL  - 35
IS  - 9
SN  - 0091-2700
UR  - https://doi.org/10.1002/j.1552-4604.1995.tb04138.x
DO  - doi:10.1002/j.1552-4604.1995.tb04138.x
SP  - 921
EP  - 940
PY  - 1995
ER  - 

TY  - JOUR
TI  - Posters
JO  - Diabetic Medicine
VL  - 23
IS  - s4
SN  - 0742-3071
UR  - https://doi.org/10.1111/j.1464-5491.2006.02037_13.x
DO  - doi:10.1111/j.1464-5491.2006.02037_13.x
SP  - 265
EP  - 410
PY  - 2006
ER  - 

TY  - JOUR
AU  - Ning, MingMing
AU  - Lopez, Mary
AU  - Cao, Jing
AU  - Buonanno, Ferdinando S.
AU  - Lo, Eng H.
TI  - Application of proteomics to cerebrovascular disease
JO  - ELECTROPHORESIS
JA  - ELECTROPHORESIS
VL  - 33
IS  - 24
SN  - 0173-0835
UR  - https://doi.org/10.1002/elps.201200481
DO  - doi:10.1002/elps.201200481
SP  - 3582
EP  - 3597
KW  - Biomarker
KW  - Cerebrovascular disease
KW  - Cerebrospinal fluid (CSF)
KW  - Mass spectrometry
KW  - Pharmaco-proteomics
KW  - Stroke
PY  - 2012
AB  - While neurovascular diseases such as ischemic and hemorrhagic stroke are the leading causes of disability in the world, the repertoire of therapeutic interventions has remained remarkably limited. There is a dire need to develop new diagnostic, prognostic, and therapeutic options. The study of proteomics is particularly enticing for cerebrovascular diseases such as stroke, which most likely involve multiple gene interactions resulting in a wide range of clinical phenotypes. Currently, rapidly progressing neuroproteomic techniques have been employed in clinical and translational research to help identify biologically relevant pathways, to understand cerebrovascular pathophysiology, and to develop novel therapeutics and diagnostics. Future integration of proteomic with genomic, transcriptomic, and metabolomic studies will add new perspectives to better understand the complexities of neurovascular injury. Here, we review cerebrovascular proteomics research in both preclinical (animal, cell culture) and clinical (blood, urine, cerebrospinal fluid, microdialyates, tissue) studies. We will also discuss the rewards, challenges, and future directions for the application of proteomics technology to the study of various disease phenotypes. To capture the dynamic range of cerebrovascular injury and repair with a translational targeted and discovery approach, we emphasize the importance of complementing innovative proteomic technology with existing molecular biology models in preclinical studies, and the need to advance pharmacoproteomics to directly probe clinical physiology and gauge therapeutic efficacy at the bedside.
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Australasian Journal on Ageing
JA  - Australas J Ageing
VL  - 37
IS  - S1
SN  - 1440-6381
UR  - https://doi.org/10.1111/ajag.12508
DO  - doi:10.1111/ajag.12508
SP  - 23
EP  - 52
PY  - 2018
ER  - 

TY  - JOUR
TI  - Pediatric State of the Art Symposium: Infantile Spasms: Emerging Therapies and Novel Mechanisms 7:00 p.m.-9:00 p.m.
JO  - Epilepsia
VL  - 49
IS  - s7
SN  - 0013-9580
UR  - https://doi.org/10.1111/j.1528-1167.2008.01871_19.x
DO  - doi:10.1111/j.1528-1167.2008.01871_19.x
SP  - 497
EP  - 497
PY  - 2008
AB  - Carl E. Stafstrom*, Douglas Nordli?, Andrew Lux? and Lionel Carmant??*Neurology, University of Wisconsin, Madison, WI; ?Neurology, Children's Memorial Hospital, Chicago, IL; ?Pediatric Neurology, British Royal Hospital for Children, Bristol, United Kingdom and ?Pediatric Neurology, Ste-Justine Hospital, Montreal, QC, Canada Summary: Infantile spasms is a catastrophic epilepsy of childhood that poses unique challenges for the clinician. An optimal therapy is lacking, and to date there has been no animal model that sufficiently replicates clinical features, so our understanding of mechanism is incomplete. Existing therapies are limited by effectiveness, availability or both. Yet, each of these challenges offers a unique opportunity to advance clinical and basic knowledge of this developmental epilepsy. This symposium will discuss recent advances about the clinical profile, therapeutic modalities, outcome, and mechanisms of infantile spasms. Dr. Nordli will review infantile spasms presentations and clinial features, especially variants. Dr. Lux will discuss current and future treatments. Dr. Carmant will discuss outcomes of infantile spasms. Finally, Dr. Stafstrom will consider emerging animal models that might shed light on infantile spasms mechanisms.
ER  - 

TY  - JOUR
TI  - Abstracts from the 27th Congress of The Scandinavian Society of Anaesthesiology and Intensive Care Medicine
JO  - Acta Anaesthesiologica Scandinavica
VL  - 47
IS  - s116
SN  - 0001-5172
UR  - https://doi.org/10.1111/j.1399-6576.2004.47s116abs.x
DO  - doi:10.1111/j.1399-6576.2004.47s116abs.x
SP  - 1
EP  - 122
PY  - 2003
ER  - 

TY  - JOUR
TI  - Abstracts from the International Veterinary Emergency and Critical Care Symposium and the European Veterinary Emergency and Critical Care Society Annual Congress, 2014
JO  - Journal of Veterinary Emergency and Critical Care
JA  - Journal of Veterinary Emergency and Critical Care
VL  - 24
IS  - S1
SN  - 1479-3261
UR  - https://doi.org/10.1111/vec.12227
DO  - doi:10.1111/vec.12227
SP  - S1
EP  - S36
PY  - 2014
ER  - 

TY  - JOUR
TI  - Oral Presentations
JO  - Sleep and Biological Rhythms
VL  - 6
IS  - s1
SN  - 1446-9235
UR  - https://doi.org/10.1111/j.1479-8425.2008.00359_2.x
DO  - doi:10.1111/j.1479-8425.2008.00359_2.x
SP  - A9
EP  - A20
PY  - 2008
ER  - 

TY  - JOUR
TI  - Poster Session 3 Cell and Molecular Biology
JO  - Obesity
VL  - 17
IS  - S2
SN  - 1930-7381
UR  - https://doi.org/10.1038/oby.2009.286
DO  - doi:10.1038/oby.2009.286
SP  - S243
EP  - S315
PY  - 2009
ER  - 

TY  - JOUR
TI  - ASBMR 2010 Annual Meeting SA0001–SA0485
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 25
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650251303
DO  - doi:10.1002/jbmr.5650251303
SP  - S136
EP  - S224
PY  - 2010
ER  - 

TY  - JOUR
AU  - MD, Jack L. Segal
AU  - Hayes, Keith C.
AU  - Brunnemann, Sherry R.
AU  - Hsieh, Jane T. C.
AU  - Potter, Patrick J.
AU  - Pathak, Mayank S.
AU  - Tierney, David S.
AU  - Mason, David
TI  - Absorption Characteristics of Sustained-Release 4-Aminopyridine (Fampridine SR) in Patients with Chronic Spinal Cord Injury
JO  - The Journal of Clinical Pharmacology
VL  - 40
IS  - 4
SN  - 0091-2700
UR  - https://doi.org/10.1177/00912700022008982
DO  - doi:10.1177/00912700022008982
SP  - 402
EP  - 409
PY  - 2000
AB  - Fampridine SR (4-aminopyridine) is a potassium channel-blocking drug currently being investigated for its therapeutic efficacy in ameliorating central conduction deficits due to demyelination in patients with spinal cord injury (SCI). The present open-label pharmacokinetic trial examined the absorption characteristics of a sustained-release form of the drug in 25 SCI subjects with chronic in complete injuries. The overall group mean Cmax of 27.7 ± 6.2 ng/mL occurred at a tmsx of 3.4 ± 1.4 hours. AUC0?12 was 210.5 ± 49.5 ng/mL?h. For paraplegics, AUCtmax was 76.02 ± 33.28 and for tetraplegics was significantly less at 51.25 ± 20.36 (p = 0.037). A statistically significant difference in the initial rate and extent of absorption, but not in total 4-AP bioavailability over the 12-hour study period, was evident between tetraplegic patients, 0.60 ± 0.23, and paraplegic patients, 0.39 ± 0.14 (p = 0.02). There was a linear correlation (p < 0.05) between the neurological level of injury and Cmax/AUCtmax. These results confirm and extend previous observations of different rates of drug absorption among SCI patients with lesions above and below the sympathetic outflow (T6) and provide evidence of the absorption characteristics of this sustained-release form of 4-aminopyridine, which is helpful for optimal dosing.
ER  - 

TY  - JOUR
TI  - ISLH 2018 Abstracts
JO  - International Journal of Laboratory Hematology
JA  - Int. Jnl. Lab. Hem.
VL  - 40
IS  - S2
SN  - 1751-5521
UR  - https://doi.org/10.1111/ijlh.12923
DO  - doi:10.1111/ijlh.12923
SP  - 1
EP  - 165
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts – Poster Presentations
JO  - Transfusion Medicine
VL  - 21
IS  - s1
SN  - 0958-7578
UR  - https://doi.org/10.1111/j.1365-3148.2011.01100.x
DO  - doi:10.1111/j.1365-3148.2011.01100.x
SP  - 20
EP  - 49
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts of Papers,** Ninety-second Annual Meeting, Marriott Rivercenter San Antonio, Texas, March 13–15, 1991
JO  - Clinical Pharmacology & Therapeutics
JA  - Clinical Pharmacology & Therapeutics
VL  - 49
IS  - 2
SN  - 0009-9236
UR  - https://doi.org/10.1038/clpt.1991.18
DO  - doi:10.1038/clpt.1991.18
SP  - 123
EP  - 201
PY  - 1991
AB  - Clinical Pharmacology and Therapeutics (1991) 49, 123?201; doi:10.1038/clpt.1991.18
ER  - 

TY  - JOUR
TI  - ACCP Winter Practice and Research Fourm — Abstracts
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 11
IS  - 1
SN  - 0277-0008
UR  - https://doi.org/10.1002/j.1875-9114.1991.tb03605.x
DO  - doi:10.1002/j.1875-9114.1991.tb03605.x
SP  - 94
EP  - 110
PY  - 1991
ER  - 

TY  - JOUR
TI  - Paper Abstract
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 67
IS  - S1
SN  - 0002-8614
UR  - https://doi.org/10.1111/jgs.15898
DO  - doi:10.1111/jgs.15898
SP  - S1
EP  - S384
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts for the 2008/2009 Annual Scientific Symposium of the Hemophilia & Thrombosis Research Society, Inc.
JO  - Haemophilia
VL  - 15
IS  - 2
SN  - 1351-8216
UR  - https://doi.org/10.1111/j.1365-2516.2009.02013.x
DO  - doi:10.1111/j.1365-2516.2009.02013.x
SP  - 626
EP  - 633
PY  - 2009
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Haemophilia
JA  - Haemophilia
VL  - 20
IS  - s3
SN  - 1351-8216
UR  - https://doi.org/10.1111/hae.12400
DO  - doi:10.1111/hae.12400
SP  - 1
EP  - 186
PY  - 2014
ER  - 

TY  - JOUR
TI  - Poster Presentations - Poster Session 1: Sunday, 30 August 2009 - Monday, 31 August 2009
JO  - Transplant International
VL  - 22
IS  - s2
SN  - 0934-0874
UR  - https://doi.org/10.1111/j.1432-2277.2009.00958.x
DO  - doi:10.1111/j.1432-2277.2009.00958.x
SP  - 95
EP  - 222
PY  - 2009
ER  - 
